Up­dat­ed: Seagen's ADC patent de­nied by US patent of­fice in bat­tle with Dai­ichi Sankyo

Seagen’s patent for a cer­tain ADC tech­nol­o­gy has been made void by the US Patent and Trade­mark Of­fice, mark­ing the lat­est twist in a long-run­ning dis­pute with Dai­ichi Sankyo that has large­ly worked in Seagen’s fa­vor to date.

The dis­agree­ment con­cerns Seagen’s patent 10,808,039 which pro­tects AD­Cs that com­prise au­ris­tatin pep­tides linked with an­ti­bod­ies via a cer­tain link­er tech­nol­o­gy that Seagen de­vel­oped dur­ing a part­ner­ship with Dai­ichi Sankyo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.